Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMH-McMaster Collaborative Care Initiative
NCT02955719Completed
- Sponsor
- Center for Addiction and Mental Health
- Start
- Mar 2016
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sertraline and venlafaxine in anxiety disorder, major depressive disorder (MDD) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by Center for Addiction and Mental Health. Primary endpoints: Change in anxiety scores at 24 months, Change in depression scores at 24 months and 1 more. Started Mar 2016; status: completed.
02
Drugs
sertralinevenlafaxine
03
Conditions
anxiety disordermajor depressive disorder (MDD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02955719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955719.